Circulation reports最新文献_第3页

An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention　- A Subgroup Analysis of the STOPDAPT-3 Trial. 分期经皮冠状动脉介入治疗患者的无阿司匹林策略- stopdpt -3试验的亚组分析

Circulation reports Pub Date : 2025-04-29 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-25-0026

Ko Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, Yuki Obayashi, Ryusuke Nishikawa, Tomoya Kimura, Kenji Ando, Satoru Suwa, Tsuyoshi Isawa, Hiroyuki Takenaka, Tetsuya Ishikawa, Takafumi Yokomatsu, Toshiya Chinen, Tatsuki Doijiri, Ken Kozuma, Yasunori Nishida, Koji Yamaguchi, Hideki Kitahara, Mitsunori Ishino, Koh Ono, Takeshi Kimura

{"title":"An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention　- A Subgroup Analysis of the STOPDAPT-3 Trial.","authors":"Ko Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, Yuki Obayashi, Ryusuke Nishikawa, Tomoya Kimura, Kenji Ando, Satoru Suwa, Tsuyoshi Isawa, Hiroyuki Takenaka, Tetsuya Ishikawa, Takafumi Yokomatsu, Toshiya Chinen, Tatsuki Doijiri, Ken Kozuma, Yasunori Nishida, Koji Yamaguchi, Hideki Kitahara, Mitsunori Ishino, Koh Ono, Takeshi Kimura","doi":"10.1253/circrep.CR-25-0026","DOIUrl":"10.1253/circrep.CR-25-0026","url":null,"abstract":"Background: No previous studies have evaluated the effect of an aspirin-free strategy for patients undergoing staged percutaneous coronary intervention (PCI).Methods and results: We conducted a post hoc subgroup analysis in patients undergoing staged PCI within 1 month in STOPDAPT-3 (n=6,002), which randomly compared prasugrel monotherapy with dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome or high bleeding risk. The co-primary endpoints were major bleeding (Bleeding Academic Research Consortium 3 or 5) and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) at 1 month. There were 814 patients undergoing staged PCI within 1 month (no-aspirin group, n=401; DAPT group, n=413). The median interval from randomization to the first staged PCI was 8 (interquartile range 5-13) days. More than 90% of the patients received assigned antiplatelet agents at all staged PCI procedures. The effect of no-aspirin relative to DAPT was not different for the co-primary bleeding (3.74% vs. 1.94%; HR 1.94; 95% CI 0.82-4.57) and cardiovascular (3.49% vs. 2.42%; HR 1.44; 95% CI 0.64-3.25) endpoints. The no-aspirin group compared with the DAPT group had a numerically higher incidence of the co-primary cardiovascular endpoint, which occurred after the first staged PCI procedure (2.49% vs. 1.21%; HR 2.07; 95% CI 0.71-6.05).Conclusions: An aspirin-free prasugrel monotherapy relative to DAPT had numerically higher risks of cardiovascular and major bleeding events in patients undergoing staged PCI at 1 month.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"451-462"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isolated Cleft of the Posterior Mitral Valve Leaflet With Papillary Muscle Abnormalities. 孤立的二尖瓣后小叶裂伴乳头肌异常。

Circulation reports Pub Date : 2025-04-26 eCollection Date: 2025-07-10 DOI: 10.1253/circrep.CR-25-0027

Kenji Harada, Yusuke Ishiyama, Sumika Wachi, Masafumi Sato, Yukiyo Ogata, Koji Kawahito, Kazuomi Kario

引用次数: 0

Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan　- Insights From the REVIEW-HF Registry. 开始服用沙克比利/缬沙坦后n端前b型利钠肽持续减少对预后的影响——来自REVIEW-HF注册的见解

Circulation reports Pub Date : 2025-04-22 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-25-0029

Yu Takigami, Shunsuke Ishii, Yuichiro Iida, Yuki Ikeda, Takeru Nabeta, Jun Oikawa, Takahito Nasu, Koshiro Kanaoka, Nobuyuki Kagiyama, Keisuke Kida, Wataru Fujimoto, Atsushi Kikuchi, Takeshi Ijichi, Tatsuhiro Shibata, Junya Ako, Shingo Matsumoto

{"title":"Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan　- Insights From the REVIEW-HF Registry.","authors":"Yu Takigami, Shunsuke Ishii, Yuichiro Iida, Yuki Ikeda, Takeru Nabeta, Jun Oikawa, Takahito Nasu, Koshiro Kanaoka, Nobuyuki Kagiyama, Keisuke Kida, Wataru Fujimoto, Atsushi Kikuchi, Takeshi Ijichi, Tatsuhiro Shibata, Junya Ako, Shingo Matsumoto","doi":"10.1253/circrep.CR-25-0029","DOIUrl":"10.1253/circrep.CR-25-0029","url":null,"abstract":"Background: Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) values after initiating sacubitril/valsartan (Sac/Val) are considered a favorable prognostic factor in patients with heart failure (HF). However the relationship between the trajectory of repeated NT-proBNP measurements and cardiovascular events after Sac/Val remains uncertain.Methods and results: A Japanese nationwide multicenter study enrolled 995 patients who were prescribed Sac/Val from August 2020 to August 2021. Of them, 434 patients who had a complete set of NT-proBNP measurements were divided into 3 groups: sustained-responder group (n=129), with ≥10% reduction in NT-proBNP at 1 month and further ≥10% reduction at 3 months; transient-responder group (n=161), with ≥10% reduction at 1 month but not at 3 months; and non-responder group (n=144), without ≥10% reduction at 1 month. There were no significant differences in the mean Sac/Val dose at each measurement point among the 3 groups. During a median follow-up of 456 (interquartile range: 371-549) days, the primary endpoint, which was either cardiovascular death or hospitalization for HF, occurred in 78 patients. Kaplan-Meier analysis revealed that the sustained-responder group had a significantly higher event-free survival rate among the 3 groups (Log-rank P<0.001).Conclusions: Repeated NT-proBNP monitoring and the pattern of the NT-proBNP trajectory after Sac/Val may be helpful in optimizing HF therapy and understanding the prognosis of HF.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"433-441"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Tailored Multidisciplinary Cardiac Rehabilitation on Patients With Cardiovascular Diseases and Multimorbidity in Convalescent Rehabilitation Hospitals in Japan　- A Multicenter, Prospective Observational Study. 量身定制的多学科心脏康复对日本康复医院心血管疾病和多种疾病患者的影响——一项多中心、前瞻性观察研究

Circulation reports Pub Date : 2025-04-22 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-24-0137

Ryo Miyazawa, Yoshitaka Iso, Satoshi Yamamoto, Tomohiro Matsuo, Tomoyuki Morisawa, Tetsuya Takahashi, Shigeru Makita, Shigeru Fujimoto

{"title":"Impact of Tailored Multidisciplinary Cardiac Rehabilitation on Patients With Cardiovascular Diseases and Multimorbidity in Convalescent Rehabilitation Hospitals in Japan　- A Multicenter, Prospective Observational Study.","authors":"Ryo Miyazawa, Yoshitaka Iso, Satoshi Yamamoto, Tomohiro Matsuo, Tomoyuki Morisawa, Tetsuya Takahashi, Shigeru Makita, Shigeru Fujimoto","doi":"10.1253/circrep.CR-24-0137","DOIUrl":"10.1253/circrep.CR-24-0137","url":null,"abstract":"Background: Data on cardiac rehabilitation (CR) outcomes in patients with cardiovascular disease (CVD), frailty, and multimorbidity in post-acute settings are limited. This study aimed to evaluate the feasibility and efficacy of individualized, multidisciplinary CR in convalescent rehabilitation hospitals (cRHs).Methods and results: This multicenter, prospective, observational study included 72 consecutive patients transferred from acute care hospitals. Personalized CR programs were implemented in cRHs. Primary outcomes were changes in the Barthel Index (BI) and functional independence measure (FIM) scores. Secondary outcomes included assessments of physical and cognitive function, and nutritional status. Mean participant age was 78.6±11.8 years. Prior to admission, 51.4% experienced acute decompensated heart failure (ADHF). The average length of stay was 59.5±39.2 days. BI and FIM scores improved from admission to discharge. The following parameters improved: Short Physical Performance Battery, knee extensor strength, comfortable gait speed, 6-min walk distance, New York Heart Association classification, and cognitive function (Mini-Mental State Examination). Discharge dispositions included 53 (73.6%) home discharges, and 19 (26.4%) outpatient CR post-discharges. Patients with post-ADHF and patients with other conditions both showed functional improvements, but ∆BI and ∆FIM were lower in the post-ADHF group.Conclusions: Tailored multidisciplinary CR in cRHs effectively improves daily living activities and physical and cognitive outcomes in patients with CVD with complex conditions. Expanded use of these hospitals may help address clinical challenges.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"403-410"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Clinical Impact of Tafamidis on Transthyretin Amyloid Cardiomyopathy　- A Decade of Experience From a Community-Based Hospital (2015-2024). 他法非地对转甲状腺素淀粉样蛋白心肌病的临床影响——来自社区医院的十年经验（2015-2024）。

Circulation reports Pub Date : 2025-04-18 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-25-0031

Toru Kubota, Seiya Kato, Daisuke Nagatomo, Akihito Ishikita, Masatsugu Nozoe, Nobuhiro Suematsu

{"title":"Real-World Clinical Impact of Tafamidis on Transthyretin Amyloid Cardiomyopathy　- A Decade of Experience From a Community-Based Hospital (2015-2024).","authors":"Toru Kubota, Seiya Kato, Daisuke Nagatomo, Akihito Ishikita, Masatsugu Nozoe, Nobuhiro Suematsu","doi":"10.1253/circrep.CR-25-0031","DOIUrl":"10.1253/circrep.CR-25-0031","url":null,"abstract":"Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a major cause of heart failure in elderly patients with left ventricular hypertrophy. Although tafamidis was approved in 2019 following the ATTR-ACT study, its real-world survival impact in community settings remains unclear.Methods and results: This retrospective study analyzed 117 patients diagnosed with ATTR-CM at a single center from 2015 to 2024, with 75 receiving tafamidis and 42 untreated. Among the 83 patients who underwent genetic testing, all had the wild-type genotype. ATTR-CM diagnoses increased significantly after the advent of 99 mTc-pyrophosphate scintigraphy and tafamidis. Kaplan-Meier analysis showed significantly longer survival in tafamidis-treated patients. Multivariate analysis identified New York Heart Association (NYHA) functional class, left ventricular wall thickness, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels, and tafamidis treatment as independent survival predictors. Tafamidis treatment was associated with significantly improved survival in patients who were younger, had a less advanced NYHA functional class, and lower levels of NT-proBNP and troponin T. In contrast, its survival benefits were marginal in patients with older age, higher NYHA functional class, elevated NT-proBNP levels, and increased troponin T levels.Conclusions: In this real-world cohort, tafamidis treatment was significantly associated with better survival in ATTR-CM patients, particularly when initiated in the early stage. Therefore, early detection and timely initiation of treatment are critical for optimizing clinical outcomes in this increasingly recognized condition.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"442-450"},"PeriodicalIF":0.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-Oxidized Low-Density Lipoprotein Antibodies Before and After Intravenous Immunoglobulin Therapy in Kawasaki Disease　- Evidence for a Potentially Protective Role. 静脉注射免疫球蛋白治疗川崎病前后的抗氧化低密度脂蛋白抗体-潜在保护作用的证据

Circulation reports Pub Date : 2025-04-16 eCollection Date: 2025-05-09 DOI: 10.1253/circrep.CR-25-0018

Zenpei Kano, Yumi Mizuno, Kenji Murata, Sagano Onoyama, Takayuki Hoshina, Yasunari Sakai, Junji Kishimoto, Koichi Kusuhara, Toshiro Hara

{"title":"Anti-Oxidized Low-Density Lipoprotein Antibodies Before and After Intravenous Immunoglobulin Therapy in Kawasaki Disease　- Evidence for a Potentially Protective Role.","authors":"Zenpei Kano, Yumi Mizuno, Kenji Murata, Sagano Onoyama, Takayuki Hoshina, Yasunari Sakai, Junji Kishimoto, Koichi Kusuhara, Toshiro Hara","doi":"10.1253/circrep.CR-25-0018","DOIUrl":"https://doi.org/10.1253/circrep.CR-25-0018","url":null,"abstract":"Background: The precise pathogenesis of Kawasaki disease (KD) remains unclear, but immune dysregulation involving damage-associated molecular patterns (DAMPs), such as oxidized low-density lipoprotein (LDL) and high mobility group box 1 (HMGB1), has been implicated. We investigated the roles of 2 anti-DAMPs antibodies in KD and their associations with inflammatory and oxidative stress markers.Methods and results: Serum levels of anti-oxidized LDL and anti-HMGB1 antibodies were measured by enzyme-linked immunosorbent assay in patients with KD and in febrile disease controls (DC). Correlations with inflammatory (C-reactive protein [CRP]) and oxidative stress (red blood cell distribution width [RDW]) markers were evaluated. Serum anti-oxidized LDL antibody levels increased significantly after intravenous immunoglobulin (IVIG) therapy in KD patients, suggesting a protective role of anti-oxidized LDL antibodies against vascular inflammation. Conversely, anti-HMGB1 antibody levels showed a decreasing trend post-IVIG. A significant correlation between antibody levels and CRP was observed in DC but not in KD patients. Furthermore, a weak inverse trend between anti-oxidized LDL antibodies and RDW-coefficient of variation was noted in KD patients.Conclusions: This study highlighted the distinct roles of anti-oxidized LDL and anti-HMGB1 antibodies during the acute phase of KD. The increase in anti-oxidized LDL antibodies following IVIG treatment suggests a protective effect, while the transient nature of anti-HMGB1 antibodies warrants further exploration.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"359-364"},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reducing the Burden of Heart Failure in Japan With Dapagliflozin　- A Cost Offset Model (IMPLICATION HF). 达格列净减轻日本心力衰竭的负担-成本抵消模型（含意HF）。

Circulation reports Pub Date : 2025-04-12 eCollection Date: 2025-06-10 DOI: 10.1253/circrep.CR-25-0022

Takuya Kishi, Eriko Kunikane, Hiroyuki Takagi, Jieling Chen, Luis Varela, Asuka Ozaki

{"title":"Reducing the Burden of Heart Failure in Japan With Dapagliflozin　- A Cost Offset Model (IMPLICATION HF).","authors":"Takuya Kishi, Eriko Kunikane, Hiroyuki Takagi, Jieling Chen, Luis Varela, Asuka Ozaki","doi":"10.1253/circrep.CR-25-0022","DOIUrl":"10.1253/circrep.CR-25-0022","url":null,"abstract":"Background: Dapagliflozin is clinically beneficial in heart failure (HF). However, how these clinical benefits translate into economic burden reduction is unclear. With IMPLICATION HF, we projected the reductions in HF events and costs that would result from dapagliflozin use in Japan using a cost offset model.Methods and results: The modeled population comprised symptomatic HF patients from the DAPA-HF and DELIVER trials. We compared the event incidences and associated costs between HF treatment with and without dapagliflozin, using the prevalence, event rates, and event costs of HF in Japan from published literature, as well as the treatment effects of dapagliflozin from the pooled meta-analysis of DAPA-HF and DELIVER. The cumulative number of events (HF hospitalization [hHF], cardiovascular [CV] death, and all-cause death) and associated costs (hHF, CV death, total) were projected. Cost offsets were calculated according to the difference in event-related costs between HF treatment with and without dapagliflozin. Dapagliflozin was estimated to prevent 63,770 hHF events (number needed to treat [NNT] 20), 11,613 CV deaths (NNT 108), and 16,141 all-cause deaths (NNT 78), as well as reducing hHF and CV death costs by JPY62.7 billion and JPY16.6 billion, totaling JPY79.3 billion over 1 year in Japan. The sensitivity analyses corroborated these findings.Conclusions: The addition of dapagliflozin to HF treatment is projected to provide economic benefits to the Japanese healthcare system.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"426-432"},"PeriodicalIF":0.0,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rationale and Design of an Exploratory, Randomized, Open-Label, Multicenter Clinical Trial to Investigate the Efficacy of Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist on Heart Failure Complicated by Chronic Obstructive Pulmonary Disease (COPD-HF Trial). 一项探索性、随机、开放标签、多中心临床试验的基本原理和设计，研究长效β2激动剂/长效毒蕈碱拮抗剂对心力衰竭合并慢性阻塞性肺疾病（COPD-HF试验）的疗效。

Circulation reports Pub Date : 2025-04-12 eCollection Date: 2025-05-09 DOI: 10.1253/circrep.CR-25-0010

Hiroya Hayashi, Shin Ito, Hiroki Fukuda, Makoto Sata, Yukio Abe, Kohei Fujimoto, Daiju Fukuda, Yohei Hanajima, Mutsuo Horii, Noriyuki Ikehara, Moriaki Inoko, Chisato Izumi, Yasuhiro Izumiya, Takafumi Nakayama, Takashi Sozu, Shigeru Toyoda, Masafumi Watanabe, Masashi Yokoi, Masafumi Kitakaze

{"title":"Rationale and Design of an Exploratory, Randomized, Open-Label, Multicenter Clinical Trial to Investigate the Efficacy of Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist on Heart Failure Complicated by Chronic Obstructive Pulmonary Disease (COPD-HF Trial).","authors":"Hiroya Hayashi, Shin Ito, Hiroki Fukuda, Makoto Sata, Yukio Abe, Kohei Fujimoto, Daiju Fukuda, Yohei Hanajima, Mutsuo Horii, Noriyuki Ikehara, Moriaki Inoko, Chisato Izumi, Yasuhiro Izumiya, Takafumi Nakayama, Takashi Sozu, Shigeru Toyoda, Masafumi Watanabe, Masashi Yokoi, Masafumi Kitakaze","doi":"10.1253/circrep.CR-25-0010","DOIUrl":"https://doi.org/10.1253/circrep.CR-25-0010","url":null,"abstract":"Background: Chronic obstructive pulmonary disease (COPD) is one of the most common comorbidities in patients with chronic heart failure (CHF). A growing number of patients are suffering from both COPD and CHF, and these conditions worsen each other. Inhaled bronchodilator therapy with long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) in combination is currently the mainstay of treatment for COPD. However, the effect of LAMA/LABA on HF with COPD remains unknown.Methods and results: The COPD-HF trial is a multicenter, double-arm, open-label, exploratory, investigator-initiated clinical study to investigate the effect of LAMA/LABA on HF in patients suffering from both COPD and CHF. The participants are randomly assigned (1 : 1) to the LAMA/LABA (tiotropium+olodaterol FDC (fixed-dose combination) 5/5 ug) group (once a day, 2 inhalations) or non-pharmacological treatments for COPD as a control group. The planned number of patients to be enrolled in this trial is 54 in total (27 in each group). The participants are followed up for 12 weeks with and without LAMA/LABA. The primary endpoint is the change in plasma B-type natriuretic peptide levels from the baseline to the end of this study (12 weeks).Conclusions: The COPD-HF trial will investigate the efficacy of LAMA/LABA on HF in patients with COPD and CHF.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"383-388"},"PeriodicalIF":0.0,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Electron Density Maps and Fused Images in Dual-Energy Cardiac Computed Tomography to Facilitate Detection of Late Iodine Enhancement. 在双能心脏计算机断层扫描中使用电子密度图和融合图像来促进晚期碘增强的检测。

Circulation reports Pub Date : 2025-04-11 eCollection Date: 2025-05-09 DOI: 10.1253/circrep.CR-24-0115

Junji Mochizuki, Yoshiki Hata, Takeshi Nakaura, Yasunori Nagayama, Masafumi Kidoh, Hiroyuki Uetani, Kaori Shiraishi, Naoki Kobayashi, Yoshinori Funama, Toshinori Hirai

{"title":"Use of Electron Density Maps and Fused Images in Dual-Energy Cardiac Computed Tomography to Facilitate Detection of Late Iodine Enhancement.","authors":"Junji Mochizuki, Yoshiki Hata, Takeshi Nakaura, Yasunori Nagayama, Masafumi Kidoh, Hiroyuki Uetani, Kaori Shiraishi, Naoki Kobayashi, Yoshinori Funama, Toshinori Hirai","doi":"10.1253/circrep.CR-24-0115","DOIUrl":"https://doi.org/10.1253/circrep.CR-24-0115","url":null,"abstract":"Background: This study aimed to optimize the fusion of quantitative maps and morphological images to improve late iodine enhancement (LIE) imaging using cardiac dual-energy computed tomography (DECT).Methods and results: We retrospectively analyzed 15 patients with suspected old myocardial infarction who underwent cardiac DECT. Virtual monochromatic images (VMI) ranging from 40 to 200 keV and quantitative maps (e.g., iodine concentration, effective atomic number, and electron density [(%EDW: percentage relative to the electron density of water)] were generated. The contrast-to-noise ratio (CNR) between LIE areas and the left ventricular (LV) blood pool and normal myocardium was calculated to determine the optimal image fusion for LIE delineation. VMI at 40 keV demonstrated superior CNR between LIE areas and normal myocardium. Electron density was significantly higher in LIE areas [105.5%EDW (interquartile range (IQR): 105.15-105.65)] than in the LV blood pool [104.4%EDW (IQR: 104.3-104.6)] and normal myocardium [104.4%EDW (IQR: 104.2-104.65)] (P<0.001). Iodine concentration and effective atomic number differed significantly between LIE areas and normal myocardium, but did not differ significantly between LIE areas and the LV blood pool. Fusion of 40 keV VMI with electron density maps yielded the highest area under the receiver operating characteristic curve (0.917).Conclusions: Fused images combining 40 keV VMI with electron density maps significantly enhanced the visualization of LIE areas on DECT, offering improved contrast and diagnostic accuracy for the assessment of myocardial territories.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"341-349"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Hemodynamics and Autonomic Function During Exercise Stress Tests in Healthy Volunteers. 经皮耳迷走神经刺激对健康志愿者运动应激试验中血流动力学和自主神经功能的影响。

Circulation reports Pub Date : 2025-04-11 eCollection Date: 2025-05-09 DOI: 10.1253/circrep.CR-24-0136

Yosuke Yoshida, Satoshi Okayama, Daisuke Fujihara, Midori Taniyama, Ayami Yamada, Megumi Fukui, Naoki Doi, Runa Takahashi, Akihiro Tanabe, Shingo Ogaki, Satoharu Hattori, Atsushi Iwai, Michitaka Nakamura, Naofumi Doi, Yoshihiko Saito

{"title":"Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Hemodynamics and Autonomic Function During Exercise Stress Tests in Healthy Volunteers.","authors":"Yosuke Yoshida, Satoshi Okayama, Daisuke Fujihara, Midori Taniyama, Ayami Yamada, Megumi Fukui, Naoki Doi, Runa Takahashi, Akihiro Tanabe, Shingo Ogaki, Satoharu Hattori, Atsushi Iwai, Michitaka Nakamura, Naofumi Doi, Yoshihiko Saito","doi":"10.1253/circrep.CR-24-0136","DOIUrl":"https://doi.org/10.1253/circrep.CR-24-0136","url":null,"abstract":"Background: Transcutaneous auricular vagus nerve stimulation (taVNS) is a potential treatment for cardiovascular disease, but data on its effects on physiological function during exercise are lacking. We investigated the effects of taVNS on hemodynamics and autonomic nervous system function during exercise stress tests.Methods and results: Sixteen healthy volunteers underwent exercise stress tests with and without taVNS in this study, with a randomized crossover design and with a washout period of at least 7 days. taVNS was set to a frequency of 100 Hz and maximum current intensity without causing discomfort. Hemodynamics and autonomic nervous system function were evaluated using plethysmography and heart rate (HR) variability, respectively. After exclusion of an outlier, data of 15 participants were analyzed. In tests with taVNS, HR was significantly reduced at maximum exercise (136.0±9.7 vs. 132.0±9.2; P<0.001) and 1 min after exercise (115.0±11.4 vs. 104.0±15.0; P<0.001), with minimal changes in blood pressure. The stroke volume and total peripheral resistance at maximum exercise significantly increased and decreased, respectively. Furthermore, low/high frequency ratio reflecting sympathetic dominance decreased at rest (3.7±2.5 vs. 1.6±1.3; P<0.001) and at maximum exercise (4.5±4.5 vs. 1.2±0.9; P<0.001).Conclusions: taVNS can reduce HR with minimal effect on blood pressure by inducing parasympathetic dominance during exercise stress tests.","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"315-322"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0